Trial · NCT04467840
Results by group134
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 134
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Supplemental Oxygen Requirement | Opaganib | Subjects not receiving supplemental oxygen for at least 24 hours by Day 14 and maintained at Day 42 | 139 | Participants | |
| Supplemental Oxygen Requirement | Placebo | Subjects not receiving supplemental oxygen for at least 24 hours by Day 14 and maintained at Day 42 | 132 | Participants | |
| Supplemental Oxygen Requirement | Opaganib | Subjects receiving supplemental oxygen (including: death, lost to follow-up, or need of oxygen) | 91 | Participants | |
| Supplemental Oxygen Requirement | Placebo | Subjects receiving supplemental oxygen (including: death, lost to follow-up, or need of oxygen) | 101 | Participants | |
| Percentage of Subjects With ≥ 2 Category Improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement by Day 14 Maintained to Day 42 | Opaganib | Subject has improvement > or equal to 2 on the WHO Ordinal Scale Day 14 and up to to Day 42 | 145 | Participants | |
| Percentage of Subjects With ≥ 2 Category Improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement by Day 14 Maintained to Day 42 | Placebo | Subject has improvement > or equal to 2 on the WHO Ordinal Scale Day 14 and up to to Day 42 | 138 | Participants | |
| Percentage of Subjects With ≥ 2 Category Improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement by Day 14 Maintained to Day 42 | Opaganib | Subject has improvement of 1 or none on the WHO Ordinal Scale (Failure) Day 14 up to Day 42 | 85 | Participants | |
| Percentage of Subjects With ≥ 2 Category Improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement by Day 14 Maintained to Day 42 | Placebo | Subject has improvement of 1 or none on the WHO Ordinal Scale (Failure) Day 14 up to Day 42 | 95 | Participants | |
| Percentage of Subjects With ≥ 2 Category Improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement by Day 14 Maintained to Day 42 | Opaganib | Failure due to not achieving improvement at Day 14 | 64 | Participants | |
| Percentage of Subjects With ≥ 2 Category Improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement by Day 14 Maintained to Day 42 | Placebo | Failure due to not achieving improvement at Day 14 | 69 | Participants | |
| Percentage of Subjects With ≥ 2 Category Improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement by Day 14 Maintained to Day 42 | Opaganib | Failure due to death up to Day 14 (before any success) | 18 | Participants | |
| Percentage of Subjects With ≥ 2 Category Improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement by Day 14 Maintained to Day 42 | Placebo | Failure due to death up to Day 14 (before any success) | 21 | Participants | |
| Percentage of Subjects With ≥ 2 Category Improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement by Day 14 Maintained to Day 42 | Opaganib | Failure due to missing status at Day 42 with prior success | 3 | Participants | |
| Percentage of Subjects With ≥ 2 Category Improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement by Day 14 Maintained to Day 42 | Placebo | Failure due to missing status at Day 42 with prior success | 5 | Participants | |
| Number of Subjects With Improvement to a Score of 3 or Less on the WHO Ordinal Scale for Clinical Improvement With a Scale Ranging From 8 Down to 0 | Opaganib | 145 | Participants | ||
| Number of Subjects With Improvement to a Score of 3 or Less on the WHO Ordinal Scale for Clinical Improvement With a Scale Ranging From 8 Down to 0 | Placebo | 138 | Participants | ||
| Number of Participants With Low Oxygen Flow Via Nasal Cannula | Opaganib | 169 | Participants | ||
| Number of Participants With Low Oxygen Flow Via Nasal Cannula | Placebo | 167 | Participants | ||
| Time to Discharge From Hospital Measured at 14 Days | Opaganib | 13.50 | 95% Confidence Interval 12.00 to 15.00 | Days | |
| Time to Discharge From Hospital Measured at 14 Days | Placebo | 14.00 | 95% Confidence Interval NA to NA | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04467840/results